The Role of I.O. In Ovarian Cancer

The odds that it's approved with the current data is low. I think with more mature data, it would have a chance. There may be a benefit when you look at the overall survival in the BEV arm. Outside of a clinical trial option, I think it's really hard to justify as a single agent. But outside of those patients, I really find it difficult to justify utilizing Iotherapy unless you buy a marker positive.